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Letters to the Editor 1221apposition; results reported here, however, suggest that in this case,
the correct apposition distance is obtained only when the location
on the strut that reflects light into the catheter is the physical
midpoint of the strut. Unfortunately, since one does not know, a
priori, from where on the strut light is reflecting back into the
catheter, a fundamental uncertainty is recognized when selecting
the point on the apparent strut to measure distance to the vessel
wall. Further studies, possibly utilizing well-characterized stents
deployed in phantom vessels, can provide a better estimate of the
location on the stent strut from where light is reflecting into the
catheter and provide a better estimate of stent apposition. Interest-
ingly, IV-OCT images of deployed bioresorbable stents are not
expected to be as susceptible to the sunflower artifact since strut
surfaces are not as highly reflective or smooth compared with metal
struts.
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Figure 2. Simulated Images and Mechanism of Sunﬂower Effect in Metallic
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Evolution and Clinical Importance
of Fibrosis in HCM
The histopathologic features of hypertrophic cardiomyopathy (HCM)
are left ventricular hypertrophy, myocyte disarray, and interstitial
fibrosis (1).
Cardiac magnetic resonance (CMR) is the gold standard for in vivo
assessment of focal myocardial fibrosis using the late gadolinium
enhancement (LGE) technique (2). This correlates with clinical risk
factors for sudden death and arrhythmias, and is predictive of adverse
outcomes including heart failure (3). It remains unclear how fibrosis
evolves and how evolution correlates with ventricular remodeling. Our
aim was to track long-term changes in CMR LGE in HCM over a
7-year follow-up period.
From 2001 to 2003, 59 patients with HCM (5 gene-positive for
sarcomeric gene mutations with electrocardiogram changes fulfilling
familial criteria) (1) underwent CMR LGE. Follow-up scans were
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Letters to the Editor1222scans. The attrition of this overall high-risk cohort from a tertiary
referral center occurred because 17 had non–magnetic resonance-
compatible devices inserted (implantable cardioverter-defibrillator,
permanent pacemaker), 4 had died, 2 had received transplants, 2 were
lost to follow-up, and 7 declined follow-up; 4 of the familial criteria
patients never developed overt HCM at follow-up. In 11, raw
DICOM (Digital Imaging and Communications in Medicine) data
were not available. Informed consent and ethical approval were
obtained.
Standard CMR examination was performed on a 1.5-T scanner
(Sonata initially, Avanto at follow-up, Siemens, Munich, Germany).
For CMR LGE imaging, 0.1 mmol/kg Magnevist (gadopentetate
dimeglumine, Bayer Healthcare, Wayne, New Jersey) was used in the
baseline scans and Dotarem (gadoteric acid, Guerbet, S.A., Villepinte,
France) was used at follow-up. Both scans used the same inversion-
recovery fast low-angle shot sequence, parameters, and operator.
Inversion times were optimized to null remote myocardium (2,3).
Blind analysis of the short-axis LGE stack from both scans was
performed for LGE extent (MRI-MASS, Medis, Leiden, the Neth-
erlands), using the “full-width half-maximum” technique (4), ex-
pressed as percentage of total left ventricular mass and per segment
(16-segment model) (3). Standard volumetric analysis was also per-
formed (CMRtools, Cardiovascular Imaging Solutions, London,
United Kingdom).
Continuous variables are reported as mean  SD; categorical
variables as percentages. Correlation between continuous variables was
reported as the Pearson correlation coefficient. Linear regression for
Figure 1. LGE and Adverse Remodeling
(A) Cine stills (top) and inversion-recovery late gadolinium enhancement (LGE)
thinning, left ventricular (LV) mass reduction, and increased LGE, as shown in th
ness; SI  signal intensity.repeated measures, taking into account individual patient clustering,
assessed the association between segmental percentages of LGE and
explanatory variables.
Seven patients (58%) had LGE at baseline (mean 78  55 g,
median 60 g, interquartile range: 43 to 133 g), ranging from 6% to 22%
of total left ventricular (LV) mass (mean 14  6%, median 13%,
interquartile range: 8% to 22%). Baseline total LGE was correlated
with LV maximal wall thickness (r2  0.56, p  0.005), LV mass (r2
 0.41, p  0.025), LV end-systolic volume (r2  0.41, p  0.024),
and inversely to LV ejection fraction (r2  0.62, p  0.002).
Segmentally, of the 192 segments, 85 (44.3%) did not have LGE. The
remaining segments had a wide range, from 0.1% to 63% (mean 14
15%, median 8.5%, interquartile range: 3% to 22%).
CMRLGE increased substantially over time. The mean percentage
increase in LGE between scans was 20  14%, ranging from 5% to
52%. The mean LGE at follow-up was 104  106 g (31  21%);
median 66 g (24%), interquartile range 29 to 151 g (16% to 43%). Two
of 5 patients without LGE at baseline, developed LGE (to 5% and
13% at the right ventricular insertion points and at the apex, respec-
tively).
Baseline CMR LGE was associated with adverse remodeling
(Fig. 1), decreasing maximum LV wall thickness (r2  0.67, p 
.001), reducing LV mass (r2 0.32, p 0.054), and a trend towards
ncreasing LV end-systolic volume (r2  0.32, p  0.055). Baseline
LGE was strongly associated with increased follow-up LGE (r2 
.64, p  0.002). Per segment, LGE increased by 14  22%
ges (middle and bottom) from the same patient after 6 years. There is wall
uantitative analysis (B). IR  inversion-recovery; MWT  maximal wall thick-ima
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Letters to the Editor 1223(interquartile range: 2.9% to 39%, p  0.001). Initial per-segment
LGE was associated with subsequent increases (r2 0.54, p 0.001).
The evolution of fibrosis is a dynamic process. Here, fibrosis
ither developed de novo, or increased over time. LGE appears to
ark a turning point, signposting a switch from increasing to
ecreasing wall thickness, and was associated with adverse remod-
ling and progressive disease. LGE represents focal myocardial
brosis. Both histological and biomarker studies suggest this is a
eterminant of LV diastolic properties and is associated with
oronary reserve, ischemia, arrhythmogenicity, and progression to
eart failure and sudden death (2). Over 7 years, de novo LGE
reas were observed, whereas established areas enlarged with
egmental thinning. LGE development was strongly predicted by
aseline LGE. This is not unexpected because fibrosis is a final
ommon pathway. However, the strength of the association raises
he possibility that focal fibrosis induces further fibrosis, supporting
he hypothesis that fibrosis may be a potential target in HCM using
ntifibrotic drugs (e.g., aldosterone antagonists) (5). The principal
imitation of this study is the high loss to follow-up: tracking
atients over 7 years was complex, particularly in this high-risk subset
f a tertiary referral HCM cohort with high rates of device implantation,
eath, or transplantation. Similarly, this cohort is unlikely to reflect a
ommunity-based HCM population.
In conclusion, over 7 years, in this cohort, HCM scar increased.
aseline CMR LGE predicted adverse remodeling, and the pres-
nce of LGE appears to represent a transition from increasing
ypertrophy to thinning. Scar begets scar, baseline CMR LGE
redicts future increases in CMR LGE.
Giovanni Quarta, MD, Agata Grasso, MD,
erdinando Pasquale, MD, Andrew S. Flett, BSc,
aniel M. Sado, BSc, Elena Bonini, MD, Cono Ariti, MSc,
anjay K. Prasad, MD, Perry M. Elliott, MD,
ames C. Moon, MD*
The Heart Hospital, 16-18 Westmoreland Street, London W1G
PH, United Kingdom. E-mail: James.Moon@uclh.nhs.uk
doi:10.1016/j.jcmg.2011.04.023
Dr. Quarta is supported by a PhD Fellowship from the University “La Sapienza” of Rome
and by a European Society of Cardiology Research Fellowship. Dr. Prasad is supported by
the National Institutes of Health Research Cardiovascular Biomedical Research Unit, a
collaboration between Royal Brompton Hospital and Imperial College, and by BHF and
CORDA. He has also received honoraria from Schering. All other authors have reported
that they have no relationships relevant to the contents of this letter to disclose.
R E F E R E N C E S
1. Maron BJ, McKenna WJ, Danielson GK, et al. American College of
Cardiology/European Society of Cardiology clinical expert consensus
document on hypertrophic cardiomyopathy: a report of the American
College of Cardiology Foundation Task Force on Clinical Expert
Consensus Documents and the European Society of Cardiology Com-
mittee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687–713.
2. Moon JC, McKennaWJ, McCrohon JA, Elliott PM, Smith GC, Pennell
DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with
gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003;
41:1561–7.
3. O’Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of
myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol
2010;56:867–74.4. Flett AS, Hasleton J, Cook C, et al. Evaluation of techniques for the
quantification of myocardial scar of differing etiology using cardiac
magnetic resonance. J Am Coll Cardiol Img 2011;4:150–6.
5. Tsybouleva N, Zhang L, Chen S, et al. Aldosterone, through novel
signaling proteins, is a fundamental molecular bridge between the genetic
defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Circulation 2004;109:1284–91.
How Should Infarct Size be
Measured on LGE Sequences?
A Call for a Change in the Guidelines
In the February 2011 issue of iJACC, we read with great interest the
article by Flett et al. (1), in which the authors compared the
reproducibility of 7 late gadolinium enhancement (LGE) quantifi-
cation techniques across 3 clinical conditions. We noted that the
authors cite in their introduction and conclusion that the 2-SD
method as a threshold for LGE is a guideline-driven recommendation
set forth by Kramer et al. (2).
However, the reference to Kramer et al. (2) does not cover this
threshold of 2-SD assessment. We did find a 2009 guideline paper
by the Society for Cardiovascular Magnetic Resonance (3) that
recommended using “more than 2SD” as a cutoff to report scar area
on LGE. Note, however, that those guidelines (3) do not specifi-
cally address 2-SD as the best method for semiautomatic scar
measurement and do not specifically assess other thresholds or
threshold methods. We think this is highly relevant because in our
experience, and that of other investigators, higher thresholds (4) or
alternative (5) methods have been recommended.
This paper is very well done and points out the need for
guideline-based assessment to standardize methods for quantitative
LGE assessment given its increasing importance in clinical and
research studies.
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